Clinical Trials on Growth Hormone-Secreting Pituitary Adenoma in Japan

Total 40 results

Novartis Pharmaceuticals

Completed

Safety and Efficacy of LCI699 in Cushing's Disease Patients

Cushings Disease | Cushing Disease

United States, Italy, France, Japan
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Cushings Disease

United States, Canada, Italy, India, Japan, Austria, Netherlands, Spain, Korea, Republic of, Germany, Thailand, France, Bulgaria, Turkey, Colombia, China, Argentina, Russian Federation, United Kingdom
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Cushing's Disease

Italy, Belgium, Japan, Germany, United Kingdom, Thailand, Spain, France, Netherlands, Turkey, Israel, China, United States, Canada, India, Argentina, Brazil, Peru, Poland, Russian Federation
Versartis Inc.

Terminated

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Growth Disorders | Pediatric Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Recruiting

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Growth Hormone Deficiency in Children

Japan
Novo Nordisk A/S

Completed

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Adult Growth Hormone Deficiency

Japan
Eli Lilly and Company

Completed

Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency

Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency (REAL 2)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, France, Germany, Japan, Sweden, United Kingdom
Novo Nordisk A/S

Recruiting

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

United States, Japan, Israel, India, Austria, Slovenia, Belgium, Brazil, France, Germany, Sweden, Turkey, Ukraine
Pfizer

Recruiting

Ngenla Subcutaneous Injection Special Investigation

Growth Hormone Deficiency Without Epiphyseal Closure

Japan
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Novo Nordisk A/S

Completed

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (NordiPAD)

Turner Syndrome | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Genetic Disorder

Japan
RECORDATI GROUP

Active, not recruiting

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Prostate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRAS

Belgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Endocrine System Diseases | Adult Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Greece, Ukraine, Australia, Canada, France, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, Spain, Turkey, United Kingdom, Germany, Korea, Republic of
Novo Nordisk A/S

Active, not recruiting

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) (REAL4)

Growth Hormone Deficiency in Children

United States, Korea, Republic of, United Kingdom, Canada, Russian Federation, India, Spain, Italy, Algeria, Austria, France, Ireland, Israel, Japan, Latvia, Poland, Serbia, Thailand, Ukraine, Germany, Slovenia, Switzerland
OPKO Health, Inc.

Completed

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Growth Hormone Deficiency

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH

Antidiuretic Hormone, Inappropriate Secretion

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women

Infertility | Ovulation Induction

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
Ascendis Pharma Endocrinology Division A/S

Completed

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)

Endocrine System Diseases | Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Turkey, Ukraine, Australia, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

Foetal Growth Problem | Small for Gestational Age

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Polycystic Ovarian Syndrome | Anovulation | Oligo-ovulation | Hypothalamic-pituitary Dysfunction

Japan
Kansai Medical University

Completed

Characterization of Macroprolactinemia

Hyperprolactinemia

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Foetal Growth Problem | Small for Gestational Age

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Acromegaly | Pituitary Gigantism

Japan
Pfizer

Completed

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

Japan
Ferring Pharmaceuticals

Completed

A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).

Central Diabetes Insipidus

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Cushing's Syndrome | Ectopic Corticotropin Syndrome | Adrenal Adenoma | Adrenal Carcinoma | AIMAH | PPNAD

Japan
Pfizer

Completed

Long Term Study With B2036-PEG

Acromegaly

Japan
Pfizer

Completed

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Well-differentiated Pancreatic Neuroendocrine Tumor

United States, China, Czechia, India, Japan, South Africa, Slovakia, France, Norway, Romania, Australia, Belgium, Hungary, Italy, Spain
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
Novartis Pharmaceuticals

Terminated

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET (COOPERATE-2)

Islet Cell Tumor

France, Spain, United Kingdom, Belgium, Hungary, Turkey, Canada, Argentina, Sweden, Italy, Thailand, Germany, Netherlands, Brazil, Australia, Japan, United States, Denmark, New Zealand
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico, Korea, Republic of
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States

Clinical Trials on Growth Hormone-Secreting Pituitary Adenoma in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations